Seqirus, a global leader in influenza prevention, announced today it has begun shipping its portfolio of seasonal influenza vaccines to customers in the U.S. for the 2020/21 influenza season.

Seqirus is one of the world's largest influenza vaccine companies and is well-positioned to supply up to 60 million doses for the U.S. market this year, depending on demand.

'We are collaborating with our partners across the industry to ensure a reliable supply of influenza vaccines throughout the season to help as many eligible people as possible get an influenza vaccination,' said Dave Ross, Vice President, North America Commercial Operations at Seqirus. 'Our healthcare system is facing an unprecedented public health crisis with COVID-19, and we are proud to provide healthcare providers and their patients with a broad range of influenza vaccine options as early as possible to help protect against influenza and help lessen the overall burden on our healthcare system.'

Seqirus has a broad portfolio of differentiated products for individuals six months of age to adults 65 years and older, presented in pre-filled syringes as well as multi-dose vials.[3],[4],[5],[6]

This year Seqirus will provide FLUAD (Influenza Vaccine, Adjuvanted), the first-and-only adjuvanted seasonal influenza vaccine approved for adults 65 and older, in addition to FLUAD Quadrivalent (Influenza Vaccine, Adjuvanted). FLUAD Quadrivalent contains an additional B strain to help prevent disease caused by all 4 influenza strains represented in the vaccine.3,4 The Seqirus 2020/21 influenza vaccine portfolio also includes FLUCELVAX QUADRIVALENT (Influenza Vaccine), a cell-based quadrivalent influenza vaccine approved for use in persons 4 years of age and older5 and AFLURIA QUADRIVALENT (Influenza Vaccine), an egg-based quadrivalent influenza vaccine approved for use in those six months of age and older.6

'Influenza vaccination is critical every year, and it is more important than ever this season as it can help reduce the risk of co-infection from seasonal influenza and COVID-19 and minimize the burden of flu on the healthcare system to preserve capacity for patients with COVID-19 and other serious disorders,' said Gregg Sylvester, MD, Chief Medical Officer at Seqirus. 'Our cell-based and adjuvant vaccine technologies are designed to address influenza prevention challenges and deliver on our commitment to safeguard people and communities against seasonal influenza.'

Seqirus produces influenza vaccines across its global manufacturing network, which includes facilities in the U.S., U.K. and Australia. The company has experienced record demand for influenza vaccines across all markets for the upcoming season and has extended production across its three manufacturing sites.

'We are exploring all possibilities to optimize supply across our global network to help meet the additional demand for the 2020/21 influenza season,' said Chris Larkins, Senior Vice President of Global Operations at Seqirus. 'We are collaborating with stakeholders across the public health community to ensure recommendations on influenza immunization practices are aligned with timing of available supply. Our focus right now is to ensure as many people as possible can be vaccinated prior to when influenza usually peaks in February and March.'

About Seasonal Influenza

Influenza is a common, highly contagious infectious disease that may cause severe illness and life-threatening complications in some people.[7] To reduce the risk of more serious outcomes, such as hospitalization and death resulting from influenza, the CDC recommends annual vaccination for individuals aged 6 months and older.1Because transmission of influenza viruses to others may occur one day before symptoms develop and up to 5 to 7 days after becoming sick, the disease can be easily transmitted to others.7 Influenza can lead to clinical symptoms varying from mild to moderate respiratory illness to severe complications, hospitalization and in some cases, death.7 Preliminary estimates from the CDC report that from October 1, 2019, through April 4, 2020, there have been an estimated 410,000 to 740,000 influenza-related hospitalizations in the U.S.[8] Since it takes about two weeks after vaccination for antibodies to develop in the body that help protect against influenza virus infection, it is recommended that people get vaccinated before influenza begins spreading in their community.1

About Seqirus

Seqirus is part of CSL Limited (ASX: CSL). As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.

About CSL

CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL - including our two businesses, CSL Behring and Seqirus provides life-saving products to more than 70 countries and employs more than 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.

Contact:

Polina Miklush

Tel: +1 (908) 608-7170

Email: Polina.Miklush@Seqirus.com

(C) 2020 Electronic News Publishing, source ENP Newswire